Aliskiren, the first approved renin inhibitor: Clinical application and safety in the treatment of hypertension
August 2nd, 2009 Posted by: admin
Abstract Hypertension is one of the most important risk factors for, and causes of, cardiovascular disease. The difficulty in achieving
a normal blood pressure range in some patients makes the rate of cardiovascular disease high. For some years renin-angiotensin
system inhibitors such as angiotensin-converting enzyme (ACE) and angiotensin receptor blockade have been objects of interest
for treatment of cardiovascular disease. Aliskiren, the first approved renin inhibitor to reach the market, is a low molecular
weight, orally active, hydrophilic nonpeptide molecule, which blocks angiotensin I generation. However it might also become
a reasonable therapeutic choice in a broad number of clinical conditions, as stable coronary artery disease, cerebrovascular
and cardiorenal disease, diabetes, and peripheral arterial disease. The aim of this review is to describe the effectiveness
and safety of aliskerin in the treatment of hypertension.
a normal blood pressure range in some patients makes the rate of cardiovascular disease high. For some years renin-angiotensin
system inhibitors such as angiotensin-converting enzyme (ACE) and angiotensin receptor blockade have been objects of interest
for treatment of cardiovascular disease. Aliskiren, the first approved renin inhibitor to reach the market, is a low molecular
weight, orally active, hydrophilic nonpeptide molecule, which blocks angiotensin I generation. However it might also become
a reasonable therapeutic choice in a broad number of clinical conditions, as stable coronary artery disease, cerebrovascular
and cardiorenal disease, diabetes, and peripheral arterial disease. The aim of this review is to describe the effectiveness
and safety of aliskerin in the treatment of hypertension.
- Content Type Journal Article
- Category Review
- DOI 10.1007/s12325-009-0050-5
- Authors
- Graziano Riccioni, Cardiology Unit “San Camillo de Lellis” Hospital Manfredonia Foggia Italy
- Nicola Vitulano, Catholic University of Rome Department of Cardiology Rome Italy
- Nicolantonio D’Orazio, University “G. D’Annunzio” Department of Biomedical Science Chieti Italy
- Fulvio Bellocci, Catholic University of Rome Department of Cardiology Rome Italy
- Journal Advances in Therapy
- Online ISSN 1865-8652
- Print ISSN 0741-238X
- Journal Volume Volume 26
- Journal Issue Volume 26, Number 7 / July, 2009
